Resultados de la búsqueda 101-110 of 8052 for Natt, Neena
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
Natt, Neena M.D.. Minnesota. Pollock, Bruce E. M.D.. Minnesota. Singh, Ravinder J. Ph.D. Minnesota Florida. Van Gompel, Jamie J. M.D.. Minnesota. Young, William ...
Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...
This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...
The purpose of this study is to evaluate how well bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Neena Natt, M.D.. endocrinólogo. Rochester, MN. Áreas de desarrollo: Tumor adrenal benigno, Hiperplasia suprarrenal congénita, Feocromocitoma ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?